TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24266960
Drug: Maintaining differences
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintaining differences in LDL-c (> 1 mmol/l)
Study: 15197210
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) supplement 1.09 g administered bid
Study: 15197210
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) liquid suspension 600 mg/d
Study: 15197210
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EPA and MA
Study: 8143399
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg felodipine ER
Study: 8143399
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg felodipine ER
Study: 8143399
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg felodipine ER
Study: 3278186
Drug: Interferon alpha-n1
Normalized name: Interferon alpha-n1 (INS)
DrugBank: Interferon alfa-n1 (DB00011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha-n1 (Wellferon) at a dose of 5 MU/m2 daily for 28 days and three times weekly for 5 months
Study: 28526381
Drug: L-GSH supplementation
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-GSH supplementation
Study: 1503442
Drug: Imipenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (500 mg four times daily)
Study: 1503442
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (gentamicin 80 mg every 8 h plus either cefuroxime 1,500 mg every 8 h or cephalothin 1,000 mg every 4 h)
Study: 26241253
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg intramuscular injection
Study: 26241253
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg intramuscular injection (Nulliparous participants)
Study: 26241253
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline injection (Nulliparous participants)
Study: 23764734
Drug: GLP-1 (7-36)
Normalized name: GLP-1 (7-36) amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (7-36) treatment in lean humans
Study: 23764734
Drug: GLP-1 (7-36)
Normalized name: GLP-1 (7-36) amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (7-36) treatment in obese humans
Study: 23764734
Drug: GLP-1 (7-36)
Normalized name: GLP-1 (7-36) amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (7-36) treatment in lean swine
Study: 23764734
Drug: GLP-1 (7-36)
Normalized name: GLP-1 (7-36) amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (7-36) treatment in obese swine
Study: 20587585
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injections (injection therapy)
Study: 12532161
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg tid plus hypocaloric diet for the first year and weight maintenance diet in year two
Study: 6449753
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide 1 mg
Study: 6449753
Drug: ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ipratropium bromide 0.1 mg
Study: 30077419
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid (ILS) injection
Study: 28832876
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 0.4 mg/g nicotine content
Study: 28832876
Drug: All nicotine
Normalized name: NICOTINE 4 mg ORAL LOZENGE [Rexall Nicotine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All nicotine doses
Study: 28832876
Drug: Higher nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher nicotine doses
Study: 26343274
Drug: Tight-control treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight-control treatment strategy using the handscan (TCHS)
Study: 23582109
Drug: Baclofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (10 mg twice daily, increasing to 25 mg over three weeks)
Study: 17434899
Drug: Docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70 mg/m² on day 2 plus oral estramustine 280 mg twice daily on days 1-5 (DE)
Study: 17434899
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² on day 1 (D)
Study: 12927020
Drug: Ascorbate (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbate (1000 mg daily)
Study: 11820041
Drug: Intensive intravenous
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intravenous insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg/dl)
Study: 11820041
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg/dl and maintenance of glucose at a level between 180 and 200 mg/dl)
Study: 9623009
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine
Study: 9623009
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no H2 blockers)
Study: 31026419
Drug: Submucosal injection
Normalized name: Mepivacaine Hydrochloride 30 mg in 1 mL SUBMUCOSAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection of tramadol
Study: 31026419
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injection (control)
Study: 17010738
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg/week
Study: 12705296
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of titanium dental implants (Im)
Study: 12705296
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of titanium dental implants (De)
Study: 10944563
Drug: Racecadotril (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (1.5 mg/kg orally every eight hours)
Study: 7047173
Drug: Penbutolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (mean dose 83 +/- 19 mg)
Study: 7047173
Drug: Penbutolol (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (same dose as above)
Study: 31850777
Drug: Conventional buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional buccal infiltration by metallic aspirating syringe
Study: 31850777
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration by computer‐controlled local anaesthetic device (Wand STA)
Study: 27454528
Drug: PDT (Photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT (Photodynamic Therapy with curcumin and blue light)
Study: 27454528
Drug: PDT +
Normalized name: Photodynamic Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT + S (Photodynamic Therapy with curcumin, surfactant SDS, and blue light)
Study: 27454528
Drug: Chlorhex (Chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhex (Chlorhexidine treatment)
Study: 24852116
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus cetuximab (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m² with cetuximab 500 mg/m²)
Study: 24852116
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m²)
Study: 22995673
Drug: LI85008F formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI85008F formulation (900 mg/day in three divided doses)
Study: 22995673
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three identical capsules)
Study: 9699761
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin and gentamicin
Study: 7794701
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg at bedtime
Study: 2927449
Drug: Lumpectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumpectomy with radiation and adjuvant chemotherapy
Study: 26273138
Drug: Preoperative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Study: 26273138
Drug: Preoperative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative dose of 100 mg flurbiprofen axetil and postoperative dose of 2 μg/kg sufentanil and 100 mg flurbiprofen axetil by PCA pump
Study: 26273138
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL placebo and postoperative dose of 2 μg/kg sufentanil and 10 mL placebo by PCA pump
Study: 26273138
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and postoperative administration of flurbiprofen axetil
Study: 23732551
Drug: MedDiet supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedDiet supplemented with extra-virgin olive oil (EVOO) 1 l/week
Study: 23732551
Drug: MedDiet supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedDiet supplemented with mixed nuts 30 g/day
Study: 21690287
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir (infused concurrently with oral oseltamivir)
Study: 21690287
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir
Study: 17116006
Drug: Lipid-lowering drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drugs (9% of subjects in 2004)
Study: 17116006
Drug: Population without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Population without lipid-lowering drugs
Study: 17116006
Drug: Population achieving
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Population achieving cholesterol levels below 5.0 mmol L(‐1) in 2004
Study: 9303254
Drug: Regular Treatment
Normalized name: Midol Regular
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Treatment Group
Study: 18029476
Drug: 1.1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 g/d eicosapentanoic acid (EPA) + docosahexanoic acid (DHA) for 6 weeks
Study: 15664094
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Study: 15664094
Drug: saline continuously
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline continuously for 48 hours at 2 mL/hour through the ONQ Pain Relief System
Study: 7607280
Drug: Recombinant Human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant Human Interferon Gamma (rIFN-gamma) administered subcutaneously three times weekly at a dose of 0.05 mg per m2
Study: 2213948
Drug: Antibiotics (cefazolin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefazolin, one dose before procedure and then q 6 h until tube removal)
Study: 975489
Drug: ICI 74,917
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 74,917 administered from a pressurized aerosol
Study: 16554455
Drug: Intranasal ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal ciclesonide (800 microg/d)
Study: 10722136
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month into treatment
Study: 10722136
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 1 week after treatment cessation
Study: 1444522
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K1 (1 mg)
Study: 1444522
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and intramuscular)
Study: 30851653
Drug: Gradual exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual exposure (EXP-G; n = 19)
Study: 29428960
Drug: Curcuma aeruginosa
Normalized name: CURCUMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma aeruginosa extract (CA-ext) applied twice daily via roll-on applicators
Study: 29428960
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion applied twice daily via roll-on applicators
Study: 25332466
Drug: Biofortified beans
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofortified beans (8.8 mg Fe, 1320 mg PA/100 g)
Study: 25332466
Drug: Control beans
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control beans (5.4 mg Fe, 980 mg PA/100 g)
Study: 16602668
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg continuous daily therapy
Study: 16602668
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg on-demand treatment
Study: 9336333
Drug: Indomethacin (0.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.66 mg/kg)
Study: 9336333
Drug: Indomethacin (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0, 0.17, 0.33, 0.66 and 1.33 mg/kg) with ethanol (0 and 1 g/kg)
Study: 9336333
Drug: Indomethacin (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0 and 0.66 mg/kg) with pentobarbital (0, 1.33 and 4 mg/kg)
Study: 1337362
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of total dietary fiber as modified guar gum
Study: 1337362
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of total dietary fiber as soy polysaccharide
Study: 1337362
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of fiber (maltodextrin)
Study: 25233346
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid emulsion (ABLE) 15 mg/kg single infusion
Study: 25233346
Drug: Liposomal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal formulation (LAmB)
Study: 21164548
Drug: NUTRIOSE supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE supplementation (17 g twice daily for 12 weeks)
Study: 8935341
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day of terbinafine for 3 months
Study: 8935341
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of terbinafine for 7 days during the first week of each month for 3 months
Study: 29801474
Drug: HF10 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF10 injection every 2 weeks for up to 4 times
Study: 24149930
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G‐GR) 600 mg am/1,200 mg pm
Study: 24149930
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G‐GR)
Study: 22215656
Drug: BicaVera solution
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BicaVera solution (bicarbonate/low-GDP PD solution)
Study: 22215656
Drug: BicaVera solution
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BicaVera solution
Study: 16275807
Drug: D-serine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (2 g/d)
Study: 18036483
Drug: Randomized controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized controlled treatment trials
Study: 15759147
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of radioiodide
Study: 15759147
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of radioiodide
Study: 10606875
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg b.w. IVIg (group A)
Study: 10606875
Drug: 1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg b.w. IVIg (group B)
Study: 10606875
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g IVIg/kg b.w. (for initial non-responders in group A)
Study: 10606875
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g IVIg/kg b.w. (for initial non-responders in group B)
Study: 28158151
Drug: 0.625% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625% capsaicin patch (CP)
Study: 28158151
Drug: Repetitive patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive patch application (0.625% CP and 0.075% capsaicin cream)
Study: 18304334
Drug: Peer mentor
Normalized name: Mentol
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peer mentor support (two-weekly contact tailored to individual needs)
Study: 10741298
Drug: Epirubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 40 mg/m2 intravenous push, Docetaxel 75 mg/m2 in 1 h infusion, Cisplatin 75 mg/m2 with pre‐ and posthydration, treatment repeated every 21 days
Study: 9095231
Drug: Conventional immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunotherapy with natural pollen extract
Study: 1396370
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (80-120 mg)
Study: 29360915
Drug: eGFR decline
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR decline below cohort median (-1.28 ml/minute/1.73 m2/2 years)
Study: 29360915
Drug: 5 ml/min/1.73
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/min/1.73 m2/year eGFR decline
Study: 25898077
Drug: Health-promoting programme
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-promoting programme implemented in treatment schools
Study: 20186629
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue perfusion via superior rectal artery
Study: 18467721
Drug: Extended-dose temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended-dose temozolomide (TMZ) 75 mg/m²/d for 6 weeks followed by a 2-week rest period
Study: 11535970
Drug: Neltenexine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neltenexine (1 sachet thrice daily for 20 days)
Study: 11535970
Drug: Sobrerol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sobrerol (1 sachet thrice daily for 20 days)
Study: 9489902
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily for 1 week
Study: 7530124
Drug: Drug-induced changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced changes
Study: 27973684
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injection (sodium hyaluronate)
Study: 27973684
Drug: Arthrocentesis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis with 0.9% NaCl solution (SS)
Study: 21438989
Drug: Topiramate (96-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (96-200 mg/day)
Study: 11703422
Drug: Miglitol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (25 mg t.i.d. for 4 weeks, 50 mg t.i.d. for 12 weeks, 100 mg t.i.d. for 16 weeks)
Study: 11703422
Drug: Miglitol combined
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol combined with metformin
Study: 11703422
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with metformin
Study: 11703422
Drug: Miglitol/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol/metformin
Study: 8190572
Drug: Carnitine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine (100 mg/kilo)
Study: 30459160
Drug: Risk-stratified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-stratified treatment approaches in major international cooperative groups
Study: 30459160
Drug: Current therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapies for infant leukemia
Study: 22853847
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg/Amlodipine 5 mg (I300/A5)
Study: 22853847
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg (I300)
Study: 22853847
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg (I150)
Study: 20929124
Drug: Astragalus granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus granule (2.25 g twice a day for two weeks)